Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab

Phase 2

Terminated

Conditions: Patients With Gastric Peritoneal Carcinomatosis

Interventions: Drug: Catumaxomab 140µg
Drug: Catumaxomab 100µg

First Posted Date: 2013-02-06

Last Posted Date: 2017-01-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 26

Registration Number: NCT01784900

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, Val de Marne, France

Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer

Phase 2

Terminated

Conditions: Patients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated

Interventions: Drug: Oxaliplatin
Drug: Folinic Acid
Drug: Fluorouracile

First Posted Date: 2012-10-26

Last Posted Date: 2016-02-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 3

Registration Number: NCT01715363

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, Val de Marne, France

Local Treatment by Thermic Destruction of Primitive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Procedure: Thermic destruction of tissue by Laser using the Novilase device

First Posted Date: 2012-10-15

Last Posted Date: 2018-03-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 16

Registration Number: NCT01706016

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
Centre Oscar Lambret, Lille, Nord, France
🇫🇷
Hopital Lariboisière, Paris, France

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Bevacizumab
Drug: Capecitabine
Drug: Irinotecan

First Posted Date: 2012-09-03

Last Posted Date: 2016-06-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 10

Registration Number: NCT01677884

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, Val de Marne, France

Confocal Micro-endoscopy in Head and Neck Cancer/Micro Endoscopie Confocale (MEC)Oto-Rhino-Laryngologie (ORL)

Not Applicable

Completed

Conditions: Malignant Pharyngo Laryngeal Tumors
Pre-malignant Pharyngo Laryngeal Tumors

Interventions: Procedure: Confocal Micro Endoscopy

First Posted Date: 2012-06-25

Last Posted Date: 2021-02-18

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 44

Registration Number: NCT01626638

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse, France

Molecular Screening for Cancer Treatment Optimization

Not Applicable

Conditions: Metastatic Solid Tumors (Any Localization)

Interventions: Procedure: Tumoral biopsy

First Posted Date: 2012-03-29

Last Posted Date: 2020-02-17

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 2150

Registration Number: NCT01566019

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, Val De Marne, France

Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma

Phase 1

Terminated

Conditions: Malignant Melanoma

Interventions: Drug: Ipilimumab
Radiation: Radiotherapy

First Posted Date: 2012-03-19

Last Posted Date: 2016-06-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 19

Registration Number: NCT01557114

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷
Gustave Roussy Cancer Campus, Villejuif, Val de Marne, France

Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP

Phase 3

Completed

Conditions: Neoplasms, Unknown Primary

Interventions: Other: No test Empiric strategy
Other: Cancer Type ID test

First Posted Date: 2012-02-28

Last Posted Date: 2020-02-17

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 243

Registration Number: NCT01540058

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷
Institut Gustave Roussy, Villejuif, Val De Marne, France
🇳🇱
Viecuri Medical Centre Venlo, Venlo, Netherlands

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Phase 2

Conditions: Primary Mediastinal Large B Cell Lymphoma

Interventions: Drug: Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab

First Posted Date: 2012-01-25

Last Posted Date: 2021-03-18

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 47

Registration Number: NCT01516567

Locations: 🇮🇹
Associazione Italiana di Ematologia ed Oncologia Pediatrica, Padova, Italy
🇨🇦
Children Oncology Group Operations centres, Monrovia, Canada
🇭🇺
2nd Dept. of Pediatrics Semmelweis Univ., Budapest, Hungary

and more 6 locations

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

Phase 3

Conditions: B-cell Non Hodgkin Lymphoma
Mature B-cell Leukemia Burkitt-type

Interventions: Drug: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
Drug: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C

First Posted Date: 2012-01-25

Last Posted Date: 2017-06-14

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 482

Registration Number: NCT01516580

Locations: 🇬🇧
University of Birmingham, Birmingham, United Kingdom
🇧🇪
University Hospitals Leuven, Leuven, Belgium
🇨🇳
The University of Hong Kong (Clinical Trials Centre), Hong-Kong, China

and more 7 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy